Implementation Strategies for a Simple Intervention to Reduce Longterm Benzodiazepine Use in Dutch Community Pharmacies
Benzodiazepines Therapeutic Use
Behavioral: training and follow-up of pharmacists
Behavioral: patient-directed discontinuation letter
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
|Official Title:||Implementation Strategies Aimed at a Simple Patient-directed Intervention to Reduce Long-term Use of Benzodiazepines in Dutch Community Pharmacies|
- percentage of general practitioners that reviewed and returned the list of longterm users.
- percentage of letters sent by the pharmacists in the four months after receiving the manual.
- percentage of long-term benzodiazepine users that managed to quit or significantly reduce their use in months 0-3, 4-6 and 10-12 after receiving the letter.
- evaluation of the implementation strategies
|Study Start Date:||November 2005|
|Study Completion Date:||December 2006|
|Primary Completion Date:||December 2006 (Final data collection date for primary outcome measure)|
In Dutch community pharmacies many projects have been undertaken in the field of pharmaceutical care, with mixed results. It is not yet clear which elements exactly contribute to the success of these projects and to implementation of pharmaceutical care.
One of the subjects to which attention is paid in community pharmacies, is the undesirable long-term use of benzodiazepines. Treatment methods for discontinuation of long-term benzodiazepine use have been studied rather extensively. A simple patient-directed discontinuation letter proved to be effective in several studies.
Comparison: a minimal intervention group (pharmacists carrying out the intervention guided by a manual only) compared to a maximal intervention group (pharmacists receiving a manual, a training aimed at better cooperation and communication with family practitioners and some support in the management of the project).
Please refer to this study by its ClinicalTrials.gov identifier: NCT00268775
Show 90 Study Locations
|Principal Investigator:||Peter G de Smet, PhD||Scientific Institute for Dutch Pharmacists, The Netherlands|
|Study Director:||Michel Wensing, PhD||Centre for Quality of Care Research Nijmegen|